« Previous
Next »
Biology of Blood and Marrow Transplantation
Volume 12, Issue 12
, Pages
1270-1276
, December 2006
Rituximab Induces Effective Clearance of Minimal Residual Disease in Molecular Relapses of Mantle Cell Lymphoma
-
Molecular monitoring of patients with MCL and time points of rituximab delivery. The R-HDS program has been described elsewhere [11]. Rituximab was delivered at the dosage of 375 mg/m2.
Molecular monitoring of patients with MCL and time points of rituximab delivery. The R-HDS program has been described elsewhere [11]. Rituximab was delivered at the dosage of 375 mg/m2.
-
Quantitative monitoring of MRD at M-rel and after rituximab treatment. Both M-rels of patient MCL-57 were studied. *During his second M-rel, this patient received only 4 rituximab courses, 2 before th
Quantitative monitoring of MRD at M-rel and after rituximab treatment. Both M-rels of patient MCL-57 were studied. *During his second M-rel, this patient received only 4 rituximab courses, 2 before the first post-treatment time point and 2 before the second time point.
PII: S1083-8791(06)00493-9
doi: 10.1016/j.bbmt.2006.07.007
© 2006 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
Biology of Blood and Marrow Transplantation
Volume 12, Issue 12
, Pages
1270-1276
, December 2006
